Project Grant R01CA314305
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $685K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the innate and adaptive immune determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy. CRS occurs in approximately 93 percent of patients receiving CAR T cell therapy, manifesting as fever, hypotension, hypoxia, and dyspnea due to rapid increases in multiple cytokines...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $127,983 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support mechanistically guided immunometabolic CAR-TIL therapy research for glioblastoma. The award funds development and evaluation of dual-engineered ME1-armored anti-PD-L1 CAR tumor-infiltrating lymphocytes in combination with intracranial administration of clemastine and bexarotene to address tumor heterogeneity and immune suppression in...
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- The National Cancer Institute awarded Mayo Clinic $387,713 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate therapy-induced senescence as a driver of immune activation and myeloid plasticity in multiple myeloma, with performance through June 30, 2031, at the Mayo Clinic campus in Rochester, Minnesota. The research examines how cytotoxic chemotherapy, specifically melphalan used in autologous stem cell transplant for newly diagnosed multiple myeloma...
- The National Cancer Institute awarded Weill Medical College of Cornell University $465,595 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to investigate immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapies. The project, titled R21CA307817, addresses a serious complication of CAR T-cell treatment for refractory B-cell malignancies. ICANS manifests as cognitive impairment and cerebral edema and remains poorly understood, limiting...
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...
- The National Cancer Institute awarded Mayo Clinic Arizona $237,660 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research elucidating the functional role of KLRG1-expressing CD4+ T conventional helper cells in the tumor microenvironment and developing a novel immunotherapy to selectively deplete KLRG1-expressing CD4+ T cells. The research investigates how KLRG1+ tumor-infiltrating T cells modify the tumor microenvironment and contribute to immune...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $624,521 on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of target cell survival by the kinases TBK1 and IKKE in T cell-mediated killing of infected and tumor cells. The research investigates how T cells use interferon-gamma for paracrine killing of target cells, with particular focus on how TBK1 and IKKE regulate susceptibility of B16...
- The National Cancer Institute awarded The University of Chicago $651,674 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop radioinducible CAR-T cell therapies that activate in response to ionizing radiation for improved treatment of solid tumors. The project investigates how radiation therapy and CAR-T cell therapy produce complementary or synergistic effects through mechanisms including increased CAR-T infiltration, target protein expression induction, and...